BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guleria P, Husain N, Shukla S, Kumar S, Parshad R, Jain D. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature. Ann Diagn Pathol 2018;34:135-41. [PMID: 29661720 DOI: 10.1016/j.anndiagpath.2018.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Girard N. Immune checkpoints in thymic epithelial tumors: challenges and opportunities. Immuno-Oncology Technology 2019;3:8-14. [DOI: 10.1016/j.iotech.2019.09.002] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Song JS, Kim D, Kwon JH, Kim HR, Choi CM, Jang SJ. Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors. Front Oncol 2019;9:1055. [PMID: 31681591 DOI: 10.3389/fonc.2019.01055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yokoyama S, Miyoshi H. Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma. J Thorac Dis 2020;12:7553-60. [PMID: 33447446 DOI: 10.21037/jtd-19-3703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Umemura S, Zhu J, Chahine JJ, Kallakury B, Chen V, Kim IK, Zhang YW, Goto K, He Y, Giaccone G. Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors. Lung Cancer 2020;147:221-8. [PMID: 32738418 DOI: 10.1016/j.lungcan.2020.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Ishihara S, Okada S, Ogi H, Kodama Y, Shimomura M, Tsunezuka H, Itoh K, Marx A, Inoue M. Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses. Lung Cancer 2020;145:40-7. [PMID: 32402921 DOI: 10.1016/j.lungcan.2020.04.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Guleria P, Kumar S, Malik PS, Jain D. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature. Pathol Oncol Res 2020;26:2363-70. [PMID: 32506394 DOI: 10.1007/s12253-020-00832-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
7 Yagi H, Nakaguro M, Ito M, Okumura Y, Takahashi S, Aoshima Y, Enomoto Y, Meguro S, Kawasaki H, Kosugi I, Shimoyama Y, Ogawa H, Tateyama H, Iwashita T. Difference in the distribution of tumor-infiltrating CD8+ T cells and FOXP3+ T cells between micronodular thymoma with lymphoid stroma and micronodular thymic carcinoma with lymphoid stroma. Pathol Int 2021;71:453-62. [PMID: 33819365 DOI: 10.1111/pin.13099] [Reference Citation Analysis]
8 Higuchi R, Goto T, Hirotsu Y, Nakagomi T, Yokoyama Y, Otake S, Amemiya K, Oyama T, Omata M. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms. J Clin Med 2019;8:E1833. [PMID: 31683962 DOI: 10.3390/jcm8111833] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
9 Yan X, Feng J, Hong B, Qian Y. The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells. Front Oncol 2021;11:662010. [PMID: 34307135 DOI: 10.3389/fonc.2021.662010] [Reference Citation Analysis]